L
Liisa Määttänen
Researcher at University of Tampere
Publications - 58
Citations - 8080
Liisa Määttänen is an academic researcher from University of Tampere. The author has contributed to research in topics: Prostate cancer screening & Prostate cancer. The author has an hindex of 26, co-authored 58 publications receiving 7543 citations. Previous affiliations of Liisa Määttänen include Helsinki University Central Hospital.
Papers
More filters
Journal ArticleDOI
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,A. Berenguer,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Bert G. Blijenberg,Sue Moss,Harry J. de Koning,Anssi Auvinen +21 more
TL;DR: PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
Journal ArticleDOI
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Teuvo L.J. Tammela,Marco Zappa,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Liisa Määttänen,Hans Lilja,Louis Denis,Franz Recker,Alvaro Paez,Chris H. Bangma,Sigrid Carlsson,Sigrid Carlsson,Donella Puliti,Arnauld Villers,Xavier Rebillard,Matti Hakama,Ulf-Håkan Stenman,Paula Kujala,Kimmo Taari,Gunnar Aus,Andreas R. Huber,Theo van der Kwast,Ron H.N. van Schaik,Harry J. de Koning,Sue Moss,Anssi Auvinen +29 more
TL;DR: In this update the ERSPC confirms a substantial reduction in prostate cancer mortality attributable to testing of PSA, with a substantially increased absolute effect at 13 years compared with findings after 9 and 11 years.
Journal ArticleDOI
Prostate-Cancer Mortality at 11 Years of Follow-up
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,Alvaro Paez,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Sigrid Carlsson,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Paula Kujala,Bert G. Blijenberg,Ulf-Håkan Stenman,Andreas R. Huber,Kimmo Taari,Matti Hakama,Sue Moss,Harry J. de Koning,Anssi Auvinen +27 more
TL;DR: Analyses after 2 additional years of follow-up consolidated the previous finding that PSA-based screening significantly reduced mortality from prostate cancer but did not affect all-cause mortality.
Journal ArticleDOI
Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)
Fritz H. Schröder,Jonas Hugosson,Sigrid Carlsson,Teuvo L.J. Tammela,Liisa Määttänen,Anssi Auvinen,Maciej Kwiatkowski,Franz Recker,Monique J. Roobol +8 more
TL;DR: PSA screening significantly reduces the risk of developing metastatic PCa, however, despite earlier diagnosis with screening, certain men still progress and develop metastases.
Journal ArticleDOI
Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network
Patrik Finne,Ralf Finne,Anssi Auvinen,Anssi Auvinen,Harri Juusela,Jussi Aro,Liisa Määttänen,Matti Hakama,Sakari Rannikko,Teuvo L.J. Tammela,Ulf-Håkan Stenman +10 more
TL;DR: At clinically relevant sensitivity levels, the MLP and LR models could reduce the number of unnecessary biopsies significantly better than the proportion of free PSA alone in men with total PSA levels in the range 4 to 10 ng/mL.